Omar Mahroo, MB, PhD, talks with host Ben Shaberman about electrophysiological testing for the retina, namely the electroretinogram (ERG), and its important role in evaluating and diagnosing inherited retinal diseases. Dr. Mahroo is a consultant ophthalmologist and retinal specialist at Moorfields Eye Hospital and St. Thomas’ Hospital in London, and Professor of Retinal Neuroscience at University College London.

Rachelle Lin, OD, MS, FAAO, an optometrist and assistant professor at the Southern California College of Optometry at Marshall B. Ketchum University, talks with host Ben Shaberman about the critical role of optometrists in providing care and low-vision resources for patients with inherited retinal diseases and other eye conditions.

Ocugen Reports Updated Results for Clinical Trial of Modifier Gene Therapy by Foundation Fighting Blindness

David Birch, PhD, at the Retina Foundation of the Southwest in Dallas, talks to host Ben Shaberman about his productive and impactful 40-plus-year career as a retinal disease researcher and clinical trial investigator. Dr. Birch also discusses the challenges and opportunities for advancing more therapies through trials and out to the people who need them.

Opus was established by the RD Fund, the Foundation’s venture philanthropy arm

September 1, 2023. Brendan Creemer talks to host Ben Shaberman about how he is taking on the diagnosis of Usher syndrome 1F by dedicating his education and career to becoming a researcher for retinal disease treatments and cures.

First cohort of patients has been dosed in Phase 1/2 clinical trial taking place in Pittsburgh and Paris

The AAV.SPR gene delivery system used in the trial is designed to more safely reach targeted retinal cells

Known as antisense oligonucleotides, the treatments performed encouragingly in ProQR’s clinical trials

Artur Cideciyan, PhD, one of the world’s foremost authorities in measuring vision and structural changes in people with retinal diseases, talks with host Ben Shaberman about current imaging tools, functional tests, and his experience as an investigator in several prominent clinical trials at the University of Pennsylvania, Scheie Eye Institute.